Abstract PS2-08-06: Biomarker analysis of patients treated with abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy from the Phase II AGAIN Study (WJOG14220B)

Authors

Midori Morita (ORCID: https://orcid.org/0000-0003-4083-4432)
Mitsuo Terada (ORCID: https://orcid.org/0000-0002-1304-2619)
Chikako Funasaka (ORCID: https://orcid.org/0000-0003-0585-4884)
Satomi Watanabe (ORCID: https://orcid.org/0000-0002-0487-8721)
Takahiro Kogawa (ORCID: https://orcid.org/0000-0003-3730-6591)
Yuko Tanabe
Sasagu Kurozumi (ORCID: https://orcid.org/0000-0002-9971-2918)
M. Shimokawa
T. Iwasa
Y. Tsuji
H. Sakai
T. Fujii
T. Takano
T. Ota
S. Tokunaga
M. Yamamoto
Y. Ozaki
K. Sugiyama
A. Yoshimura
M. Nishimura

Institutions

SHOWA Medical University (JP)
Gunma University (JP)
Yamaguchi University (JP)
Nagoya City University (JP)
Kindai University Hospital (JP)
Osaka City General Hospital (JP)
National Hospital Organization Hokkaido Medical Center (JP)
Tonan Hospital (JP)
Kishiwada City Hospital (JP)
Izumi City General Hospital (JP)
Aichi Cancer Center (JP)
Japanese Red Cross Narita Hospital (JP)
National Cancer Center Hospital East (JP)
Nagoya Medical Center (JP)
Hyogo Prefectural Cancer Center (JP)
Toranomon Hospital (JP)
Japanese Foundation For Cancer Research (JP)
Kindai University (JP)

Publication Details

Journal: Clinical Cancer Research
Published: 2026-02-17
DOI: https://doi.org/10.1158/1557-3265.sabcs25-ps2-08-06
Primary Topic: Advanced Breast Cancer Therapies
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Abstract PS2-08-06: Biomarker analysis of patients treated with abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy from the Phase II AGAIN Study (WJOG14220B)

Midori Morita, Mitsuo Terada, Chikako Funasaka, Satomi Watanabe et al.

Feb 17, 2026

Clinical Cancer Research

Advanced Breast Cancer Therapies

article

Abstract PS2-08-06: Biomarker analysis of patients treated with abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy from the Phase II AGAIN Study (WJOG14220B)

Midori Morita, Mitsuo Terada, Chikako Funasaka, Satomi Watanabe, Takahiro Kogawa, Yuko Tanabe, Sasagu Kurozumi, M. Shimokawa, T. Iwasa, Y. Tsuji, H. Sakai, T. Fujii, T. Takano, T. Ota, S. Tokunaga, M. Yamamoto, Y. Ozaki, K. Sugiyama, A. Yoshimura, M. Nishimura

February 17, 2026article en

Abstract

No abstract available for this paper.

Clinical Cancer ResearchVol. 32(4_Supplement)

SHOWA Medical University (JP), Gunma University (JP), Yamaguchi University (JP), Nagoya City University (JP), Kindai University Hospital (JP), Osaka City General Hospital (JP), National Hospital Organization Hokkaido Medical Center (JP), Tonan Hospital (JP), Kishiwada City Hospital (JP), Izumi City General Hospital (JP), Aichi Cancer Center (JP), Japanese Red Cross Narita Hospital (JP), National Cancer Center Hospital East (JP), Nagoya Medical Center (JP), Hyogo Prefectural Cancer Center (JP), Toranomon Hospital (JP), Japanese Foundation For Cancer Research (JP), Kindai University (JP)

Good health and well-being

Openalex Percentile: Top 48%

Advanced Breast Cancer Therapies

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Abstract PS2-08-06: Biomarker analysis of patients treated with abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy from the Phase II AGAIN Study (WJOG14220B) — Midori Morita, Mitsuo Terada, et al. · Clinical Cancer Research (2026) | TGRS Research Map | TGRS